Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
132M
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
34.1M
-
Shares change
-
+753K
-
Total reported value, excl. options
-
$637M
-
Value change
-
+$14.4M
-
Put/Call ratio
-
0.01
-
Number of buys
-
48
-
Number of sells
-
-49
-
Price
-
$18.70
Significant Holders of RAPT Therapeutics, Inc. - Common Stock (RAPT) as of Q2 2023
120 filings reported holding RAPT - RAPT Therapeutics, Inc. - Common Stock as of Q2 2023.
RAPT Therapeutics, Inc. - Common Stock (RAPT) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.1M shares
of 132M outstanding shares and own 25.79% of the company stock.
Largest 10 shareholders include FMR LLC (4.19M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.49M shares), Column Group LLC (2.68M shares), PERCEPTIVE ADVISORS LLC (2.29M shares), BlackRock Inc. (2.17M shares), VANGUARD GROUP INC (1.95M shares), STATE STREET CORP (1.7M shares), GREAT POINT PARTNERS LLC (1.47M shares), ORBIMED ADVISORS LLC (1.25M shares), and T. Rowe Price Investment Management, Inc. (1.24M shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.